| Literature DB >> 36205804 |
Stefano Negrini1,2, Kristian Borg3, Anne Cusick4, Giorgio Ferriero5,6, Walter R Frontera7, Douglas P Gross8, Allen Heinemann9,10, Wendy Machalicek11, Ann Patricia Moore12, Randolph J Nudo13, Dominic Pérennou14, Henk Stam15, Carlotte Kiekens16.
Abstract
Entities:
Mesh:
Year: 2022 PMID: 36205804 PMCID: PMC9542461 DOI: 10.1007/s10926-022-10071-6
Source DB: PubMed Journal: J Occup Rehabil ISSN: 1053-0487
Recommendations by the World Health Organization Evidence-informed Policy Network (EVIPNet) in the document “Together on the road to evidence-informed decision-making for health in the post-pandemic era: a call for action”
| We call on governments and intergovernmental organizations: | |
| 1.1 | to assess, create and strengthen institutional structures and processes that are agile and can rapidly respond to decision-makers’ needs, while drawing upon a range of types of evidence that are contextualized and actionable to inform decision-making; |
| to ensure that these structures and processes are (i) demand-driven, (ii) ethical, (iii) multisectoral and multidisciplinary in nature, (iv) adapted to the local context, and (v) positioned to coordinate their resources effectively to avoid duplication of evidence production; | |
| to support and advocate for routine and transparent evidence-to-policy co-production processes that are equity-oriented, inclusive and foster multisectoral participation of all stakeholders, including systematic approaches to elicit input and engage citizens to encourage democratic legitimacy, accountability and transparent governance; | |
| to demonstrate leadership and commitment by taking action, such as adopting a formal resolution, to accelerate, advance and institutionalize evidence-informed decision making at the global, regional and national levels to better prepare for and confront future health emergencies as well as routine societal challenges; | |
| to promote a climate of and build a culture for evidence-informed decision-making so that individual stakeholders, institutions and societies as a whole value, understand and routinely use evidence; | |
| to strengthen monitoring and evaluation of evidence-informed decision-making processes, including impact assessment of measures, to enhance the knowledge base of evidence-to-policy activities and their institutionalization, improve interventions, and reinforce accountability and learning | |
| We strongly encourage: | |
| 2.1 | intergovernmental organizations to develop, provide access to and disseminate agreed upon norms, standards and tools for evidence-informed decision-making, ensuring rigorous, transparent and systematic processes, including the development of a tool that describes key characteristics of national institutional structures and processes; |
| 2.2 | intergovernmental organizations to collect, disseminate and support the scaling up of good practices and lessons learned on national, regional and international evidence informed decision-making activities, and to provide opportunities for peer support and learning; |
| 2.3 | governments and intergovernmental organizations to collaborate to adhere to standards for evidence-informed decision-making |
| We stress the importance for: | |
| 3.1 | intergovernmental organizations to provide technical support and assistance to Member States to strengthen their national institutional capacity, structures and processes to support evidence-informed decision-making processes in a timely and responsive manner, and build trust and legitimacy around evidence-informed decision making; |
| 3.2 | governments to ensure that a critical mass of people is trained across the evidence spectrum and in using evidence to formulate policies, e.g. by promoting the inclusion of evidence-informed decision-making courses in the curricula of universities and other regular training programmes; |
| 3.3 | governments and intergovernmental organizations to increase synergies and systemic capacities by strengthening collaboration across the evidence ecosystem and moving away from siloed approaches, to coordinate and integrate research, data and expertise across stakeholders and sectors in transparent ways for more effective and timely decision-making; |
| 3.4 | governments and intergovernmental organizations to secure sustainable funding and incentives for evidence-informed decision-making activities |
| We invite: | |
| 4.1 | intergovernmental organizations to develop and provide global public goods, such as relevant, timely and high-quality global evidence syntheses and guidelines that are easily adaptable to and can be used at local levels; |
| 4.2 | intergovernmental organizations and other international, regional and national stakeholders to establish and maintain comprehensive evidence repositories to provide easy and affordable access for countries of all income levels; |
| 4.3 | governments and intergovernmental organizations to advocate for “Open Science”, a movement to make scientific research accessible, and to ensure that policy-makers have easy access to contextualized sources of evidence for health |
Recommendations by the Global Commission on Evidence promoted by the COVID-19 Evidence Network to support Decision-making (COVID-END). In bold are the 8 main recommendations
| All decision-makers, evidence intermediaries and impact-oriented evidence producers | |
| All decision-makers should pay attention when a claim is being made and ask about the quality and applicability of the evidence on which the claim is based | |
| Multilateral organizations | |
| Government policymakers | |
| Government policymakers should ensure that the executive and legislative branches of government have access to the staff, partnerships and other resources needed for evidence support | |
| Government policymakers should select their science advisors based on their ability to find, contextualize and communicate diverse forms of evidence, and to sustain a high-performing evidence-support system | |
| Government policymakers should hold advisory bodies to higher standards in their use of evidence | |
| Government policymakers should complement their general support for data collection and sharing with specific support for a more diversified evidence base that can inform decision-making in equity sensitive ways | |
| Government policymakers should incentivize open science as a key enabler for using evidence in decision-making | |
| Government policymakers should ensure that regulatory regimes and ongoing validation schemes for artificial intelligence (AI) optimize AI’s benefits for evidence-support systems and minimize its harms | |
| Organizational leaders, professionals and citizens | |
| Every significant organizational association, professional body and impact-oriented civil-society group should review its contributions to its national (or subnational) evidence-support system (and broader evidence infrastructure), fill the gaps both internally and through partnerships, and report to its members on their progress | |
| Evidence intermediaries | |
| All evidence intermediaries should – in a timely and responsive way – support the use of best evidence to answer the question being asked (or that should be asked given the decision-maker’s area of interest) | |
| Impact-oriented evidence producers | |
| Evidence groups should anticipate and fill gaps in, and adhere to standards for, their respective forms of evidence | |
| Evidence groups should play to their comparative advantages, collaborate with groups that have complementary comparative advantages, and help to build a better evidence-support system in their country and a better global evidence architecture | |
| Evidence groups should be open to adapting innovations from other sectors | |
| Evidence groups should ensure they have the agility to pivot to new topics when global emergencies strike | |
| Evidence groups should prepare ‘derivative products’ that communicate what we know (and with what certainty we know it) in ways that make sense to their target audiences | |
| Academic institutions, and their public funders, should incentivize faculty members to contribute to their national (or sub-national) evidence-support system and to evidence-related global public goods | |
| Journal publishers should improve the ways in which they support the use of best evidence | |
| Funders | |
Key recommendations from “Cochrane Convenes (2022): Preparing for and responding to global health emergencies: Learnings from the COVID-19 evidence response and recommendations for the future.”
| At system level, in order to prepare to serve the needs of decision makers equitably and with high-quality evidence during the next global health emergency, Cochrane Convenes participants recommend: | |
| providing more financial support for evidence generation, communication, networks and infrastructure in low- and middle-income countries | |
| working with national and international stakeholders to describe the ideal global evidence system, or service, and what this might require – and then advocating for the necessary conditions | |
| working towards greater transparency about how (and what) evidence is used in decision making | |
| harnessing research commissioning and financing as tools to help identify, prioritize, fund and meet national and international research needs equitably | |
| At a research and research institution level, Cochrane Convenes participants recommend: | |
| further developing or reviewing research tools, processes, methods and standards to meet the challenges of rapid onset global health emergencies more effectively | |
| investing in and using new technology to facilitate review processes (using study repositories and databases, crowd screening, and artificial intelligence) and enhance transparency and data sharing | |
| evaluating the suitability of faster, more agile editorial processes and formats (rapid/ living reviews and preprints) | |
| investing time and resources in science communications on an ongoing basis – including in people, technology and learning, as well as evaluating what works | |
| Other recommendations highlight the value of being good partners in support of the changes and recommendations made at system and communication levels, including: | |
| being alert to – and communicating about – fraudulent trials and studies | |
| reducing duplication and research waste | |
| playing a role in building capacity in low- and middle-income countries | |
| engaging with evidence users – directly and in partnership with others – to help communicate uncertainty and the evolving nature of the evidence | |
| Top-line recommendations on what is needed include: | |
| researching what works (and where) in terms of both communicating uncertainty and countering mis/disinformation | |
| building trust through increased collaboration between evidence producers, evidence users and clinical partners | |
| increasing transparency around public decision-making processes | |
| considering a form of accreditation and quality approval for official sources of evidence that has met certain quality-control standards making it easier for people to access trustworthy information – considering, for example, the increased engagement of information scientists to help increase both ‘push’ (ensuring people receive and can act on evidence) and ‘pull’ (helping people to find and use evidence), as well as using non traditional formats, channels and champions | |
| forming multidisciplinary coalitions to hold those deliberately creating and sharing mis/disinformation to account | |